DTMT NETWORK
The United Kingdom government has advised that people who have a history of immediate-onset anaphylaxis to a vaccine, medicine or food should not receive the Pfizer BioNtech vaccine.

“A second dose should not be given to anyone who has experienced anaphylaxis following administration of the first dose of this vaccine,” adds the advice issued by Dr June Raine, Chief Executive of the Medicines and Healthcare Products Regulatory Agency (MHRA).

Dr Raine's advice came following two reports of anaphylaxis and one report of a possible allergic reaction following immunization.

Dr Raine added, “On December 9, 2020, we convened an Expert Group of the Commission on Human Medicines’ (CHM), attended by experts in Allergy and Clinical Immunology, to robustly review these reports to consider any possible mitigation on the rare risk of anaphylaxis.

Anaphylaxis is a known, although very rare, side effect with any vaccine. Most people will not get anaphylaxis and the benefits in protecting people against Covid-19 outweigh the risks.

Dr Raine said, “Anyone due to receive their vaccine should continue with their appointment and discuss any questions or medical history of serious allergies with the healthcare professional prior to getting the jab.”

He assured, “You can be completely confident that this vaccine has met the MHRA’s robust standards of safety, quality and effectiveness. The safety data has also been critically assessed by the government’s independent advisory body, the Commission on Human Medicines. No vaccine would be approved unless it meets these stringent standards – that you can be sure.”

“We have in place a robust and proactive safety monitoring strategy for Covid vaccines which allows for rapid, real-time safety monitoring at population level. The fact that these incidents were picked up and reviewed shows that to be the case," explained Dr Raine.